Michelucci A., Manzo Margiotta F., Panduri S., Tonini A., Romanelli M., Morganti R. et al. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatol Ther. 2022;35(4):e15339. https://doi.org/10.1111/dth.15339..
DOI: 10.1111/dth.15339
Gisondi P., Talamonti M., Chiricozzi A., Piaserico S., Amerio P., Balato A. et al. Treat-to-Target Approach for the Management of Patients with Moderate-toSevere Plaque Psoriasis: Consensus Recommendations. Dermatol Ther (Heidelb). 2021;11(1):235–252. https://doi.org/10.1007/s13555-020-00475-8..
DOI: 10.1007/s13555-020-00475-8
Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350. https://doi.org/10.1038/jid.2009.59..
DOI: 10.1038/jid.2009.59
Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725. https://doi.org/10.1016/s1074-7613(00)00070-4..
DOI: 10.1016/s1074-7613(00)00070-4
Langley R.G., Tsai T.F., Flavin S., Song M., Randazzo B., Wasfi Y. et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, doubleblind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. https://doi.org/10.1111/bjd.15750..
DOI: 10.1111/bjd.15750
Sofen H., Smith S., Matheson R.T., Leonardi C.L., Calderon C., Brodmerkel C. et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040. https://doi.org/10.1016/j.jaci.2014.01.025..
DOI: 10.1016/j.jaci.2014.01.025
Markham A. Guselkumab: First Global Approval. Drugs. 2017;77(13):1487–1492. https://doi.org/10.1007/s40265-017-0800-7..
DOI: 10.1007/s40265-017-0800-7
Nogueira M., Torres T. Guselkumab for the treatment of psoriasis – evidence to date. Drugs Context. 2019;8:212594. https://doi.org/10.7573/dic.212594..
DOI: 10.7573/dic.212594
Gordon K.B., Duffin K.C., Bissonnette R., Prinz J.C., Wasfi Y., Li S. et al. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015;373(2):136–144. https://doi.org/10.1056/NEJMoa1501646..
DOI: 10.1056/NEJMoa1501646
Blauvelt A., Papp K.A., Griffiths C.E., Randazzo B., Wasfi Y., Shen Y.K. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. https://doi.org/10.1016/j.jaad.2016.11.041..
DOI: 10.1016/j.jaad.2016.11.041
Reich K., Armstrong A.W., Foley P., Song M., Wasfi Y., Randazzo B. et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. https://doi.org/10.1016/j.jaad.2016.11.042..
DOI: 10.1016/j.jaad.2016.11.042
Reich K., Armstrong A.W., Langley R.G., Flavin S., Randazzo B., Li S. et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839. https://doi.org/10.1016/S0140-6736(19)31773-8..
DOI: 10.1016/S0140-6736(19)31773-8
Benhadou F., Ghislain P.D., Guiot F., Willaert F., Del Marmol V., Lambert J. et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(12):e837–e839. https://doi.org/10.1111/jdv.16715..
DOI: 10.1111/jdv.16715
Zhuang J.Y., Li J.S., Zhong Y.Q., Zhang F.F., Li X.Z., Su H. et al. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population. Dermatol Ther. 2021;34(5):e15054. https://doi.org/10.1111/dth.15054..
DOI: 10.1111/dth.15054
Budu-Aggrey A., Brumpton B., Tyrrell J., Watkins S., Modalsli E.H., Celis- Morales C. et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019;16(1):e1002739. https://doi.org/10.1371/journal.pmed.1002739..
DOI: 10.1371/journal.pmed.1002739
Paroutoglou K., Papadavid E., Christodoulatos G.S., Dalamaga M. Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations. Curr Obes Rep. 2020;9(3):165–178. https://doi.org/10.1007/s13679-020-00380-3..
DOI: 10.1007/s13679-020-00380-3
Foley P., Gordon K., Griffiths C.E.M., Wasfi Y., Randazzo B., Song M. et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018;154(6):676–683. https://doi.org/10.1001/jamadermatol.2018.0793..
DOI: 10.1001/jamadermatol.2018.0793
Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24(11):1720–1740. https://doi.org/10.1016/s0149-2918(02)80075-3..
DOI: 10.1016/s0149-2918(02)80075-3
Mayer L., Young Y. Infusion reactions and their management. Gastroenterol Clin North Am. 2006;35(4):857–866. https://doi.org/10.1016/j.gtc.2006.09.006..
DOI: 10.1016/j.gtc.2006.09.006
Hsu L., Armstrong A.W. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9(10):949–958. https://doi.org/10.1586/1744666X.2013.836060..
DOI: 10.1586/1744666X.2013.836060
Thomas L.W., Lee E.B., Wu J.J. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. J Dermatolog Treat. 2019;30(2):110–116. https://doi.org/10.1080/09546634.2018.1473552..
DOI: 10.1080/09546634.2018.1473552
Norden A., Moon J.Y., Javadi S.S., Munawar L., Maul J.T., Wu J.J. Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(8):1171–1177. https://doi.org/10.1111/jdv.18042..
DOI: 10.1111/jdv.18042
Gordon K.B., Armstrong A.W., Foley P., Song M., Shen Y.K., Li S. et al. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019;139(12):2437–2446.e1. https://doi.org/10.1016/j.jid.2019.05.016..
DOI: 10.1016/j.jid.2019.05.016
Ferris L.K., Ott E., Jiang J., Hong H.C., Li S., Han C., Baran W. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. J Dermatolog Treat. 2020;31(2):152–159. https://doi.org/10.1080/09546634.2019.1587145..
DOI: 10.1080/09546634.2019.1587145
Ohtsuki M., Kubo H., Morishima H., Goto R., Zheng R., Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053–1062. https://doi.org/10.1111/1346-8138.14504..
DOI: 10.1111/1346-8138.14504
Zhu Y., Marini J.C., Song M., Randazzo B., Shen Y.K., Li S., Zhou H. Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderateto-Severe Plaque Psoriasis. J Invest Dermatol. 2019;139(8):1830–1834.e6. https://doi.org/10.1016/j.jid.2019.02.018..
DOI: 10.1016/j.jid.2019.02.018
Ruggiero A., Fabbrocini G., Cinelli E., Megna M. Guselkumab and Risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021;85(4):1028–1030. https://doi.org/10.1016/j.jaad.2021.01.025..
DOI: 10.1016/j.jaad.2021.01.025
Ruggiero A., Fabbrocini G., Cinelli E., Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673. https://doi.org/10.1111/dth.14673..
DOI: 10.1111/dth.14673
Ruiz-Villaverde R., Rodriguez-Fernandez-Freire L., Armario-Hita J.C., Pérez-Gil A., Chinchay F.V., Galán-Gutiérrez M. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis. Dermatol Ther. 2022;35(10):e15760. https://doi.org/10.1111/dth.15760..
DOI: 10.1111/dth.15760